Back

Balancing safety and efficacy: Factor XIa inhibitors vs. DOACs in atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Anticoagulation in atrial fibrillation: real-world experience Oral Anticoagulation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Miss Jacinthe Khater

Beirut (Lebanon)

6 More presentations in this session

Presentation thumbnail
The efficacy and safety of edoxaban compared to warfarin in patients with atrial fibrillation with different clinical phenotypes: a meta-analysis of randomized controlled trials
Doctor T. Chao (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Real-world outcomes of oral anticoagulation in atrial fibrillation patients with high bleeding and stroke risks: evidence from three international registries from Middle East, Europe and Asia-Pacific
Doctor A. Askarinejad (Liverpool, GB)
Abstract Slides Video
Presentation thumbnail
Analysis of left atrial thrombus in atrial flutter and atrial fibrillation
Professor M. Wybraniec (Katowice, PL)
Abstract Slides Video
Presentation thumbnail
Risk of adverse events in non-anticoagulated european and asian patients with atrial fibrillation and clinical complexity: an analysis from two prospective observational registries
Doctor E. Tartaglia (Modena, IT)
Abstract Slides Video
Presentation thumbnail
10-year trend of antithrombotic therapy status and clinical outcomes of young patients with atrial fibrillation The Fushimi AF Registry
Doctor N. Masunaga (Kyoto, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Anticoagulation in atrial fibrillation: real-world experience

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Use of factor XI inhibitors compared with DOACs in atrial fibrillation and thromboembolism prevention: a systematic review and meta-analysis of randomized-controlled trials
thumbnail
Congress Presentation
Safety and efficacy of factor XI/XIa inhibitors compared to factor Xa inhibitors for stroke prophylaxis in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials
thumbnail
Congress Session
What does the future hold for factor XIa vs. factor Xa inhibitors in atrial fibrillation, acute coronary syndrome and stroke?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources